Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.

If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.

The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.

Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.

But the Galaxies Lung-201 trial features notable omissions, plus toxicity.